27.56MMarket Cap-939P/E (TTM)
1.465High1.411Low17.85KVolume1.440Open1.420Pre Close25.53KTurnover0.12%Turnover RatioLossP/E (Static)18.81MShares4.59052wk High0.92P/B21.57MFloat Cap1.15052wk Low--Dividend TTM14.72MShs Float44.900Historical High--Div YieldTTM3.79%Amplitude1.150Historical Low1.430Avg Price1Lot Size
Enlivex Therapeutics Stock Forum
NEWS
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
Which is more important when picking a trade:
Earning or FDA outcome
Acquisition or Market sentiment
Happy to learn from friends here.
$Enlivex Therapeutics(ENLV.US)$
$Akebia Therapeutics(AKBA.US)$
$Rekor Systems(REKR.US)$
$OncoCyte(OCX.US)$
NEWS
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
NEWS
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Enlivex Therapeutics (ENLV) announces positive results from Phase II study of Allocetra™ in sepsis patients, showing significant reductions in SOFA scores and mortality rates. The study indicates a potential market opportunity for Allocetra™ in high-risk sepsis patients originating from urinary tract infections.
Positive indication of effect and safety result...
Must Delete Now 😡🔥👎
No comment yet